Bailard Inc. Increases Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Bailard Inc. lifted its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 1.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 17,080 shares of the biopharmaceutical company’s stock after buying an additional 200 shares during the period. Bailard Inc.’s holdings in Intra-Cellular Therapies were worth $1,223,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Quantum Private Wealth LLC raised its holdings in Intra-Cellular Therapies by 64.7% in the 4th quarter. Quantum Private Wealth LLC now owns 23,705 shares of the biopharmaceutical company’s stock valued at $1,698,000 after acquiring an additional 9,308 shares during the last quarter. HealthInvest Partners AB acquired a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth $877,000. Phocas Financial Corp. acquired a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth $1,949,000. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in shares of Intra-Cellular Therapies by 209.4% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 154,700 shares of the biopharmaceutical company’s stock worth $8,058,000 after buying an additional 104,700 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Intra-Cellular Therapies by 36.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 974,914 shares of the biopharmaceutical company’s stock worth $50,783,000 after buying an additional 259,424 shares during the last quarter. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Insider Transactions at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, CFO Lawrence J. Hineline sold 13,337 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $69.43, for a total value of $925,987.91. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CFO Lawrence J. Hineline sold 13,337 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $69.43, for a total transaction of $925,987.91. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Michael Halstead sold 7,907 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $69.53, for a total transaction of $549,773.71. Following the transaction, the executive vice president now owns 29,700 shares in the company, valued at approximately $2,065,041. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 168,487 shares of company stock valued at $11,364,950. Insiders own 3.40% of the company’s stock.

Intra-Cellular Therapies Trading Up 1.4 %

NASDAQ:ITCI traded up $1.04 on Friday, reaching $73.17. The stock had a trading volume of 100,571 shares, compared to its average volume of 932,354. The company has a 50-day moving average of $69.38 and a 200 day moving average of $64.63. The stock has a market cap of $7.08 billion, a P/E ratio of -49.40 and a beta of 1.02. Intra-Cellular Therapies, Inc. has a 12-month low of $45.50 and a 12-month high of $84.89.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.14. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The business had revenue of $132.10 million for the quarter, compared to analysts’ expectations of $135.97 million. During the same quarter last year, the company posted ($0.45) earnings per share. The company’s quarterly revenue was up 50.3% compared to the same quarter last year. On average, equities analysts predict that Intra-Cellular Therapies, Inc. will post -0.62 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. The Goldman Sachs Group upped their price objective on Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a “neutral” rating in a report on Wednesday, April 17th. TD Cowen upped their price objective on Intra-Cellular Therapies from $80.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Royal Bank of Canada restated an “outperform” rating and set a $86.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, April 3rd. Needham & Company LLC increased their price target on Intra-Cellular Therapies from $82.00 to $90.00 and gave the company a “buy” rating in a report on Monday. Finally, Bank of America increased their price target on Intra-Cellular Therapies from $82.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $90.17.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.